Creating a favourable framework for tissue-agnostic research – ESMO
ESMO shared on LinkedIn:
“Advances in Precision Oncology are reshaping Cancer Care, moving towards a biology-based approach rather than the traditional organ-based one. As highlighted by Fabrice Andre, ESMO President-Elect, this approach has often delayed Patient Access to innovative treatments.
ESMO is actively working to create a favourable framework for tissue-agnostic research. The newly released ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) aims to standardise the assessment of molecularly guided therapies, facilitating a common understanding among all stakeholders in the clinical research community.
In this context, ESMO has also updated its recommendations for next-generation sequencing (NGS), expanding testing criteria to include a broader range of tumour types, including hashtagRareCancers. ESMO is committed to supporting this change through resources designed specifically for medical oncologists.
To learn more read the interview in the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023